FTC Weight-Loss Advertising Rules
Substantiation and testimonials.
Substantiation and testimonials.
Across the 20 programmes we price, all-in cost runs from $145 a month at the starter dose, with the cheapest first year at about $1,740 (NexLife, $145 a month at a 2.4 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
All-in monthly cost at 2.4 mg
How to verify this yourself
Regulatory summaries age badly, this one included. FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
Proposal, enforcement, or rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is about claims rather than a finding of patient harm. Only a final rule changes what is lawful. If a regulatory story is being used to sell you something urgently, the urgency is the marketing.
What it changes for a patient
Rarely the prescription requirement, the pharmacy licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Proposal, enforcement, or final rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is a formal statement that specific claims are unlawful, not a finding of patient harm. Only a final rule changes what may lawfully be done.
If a regulatory story is being used to sell you something urgently, the urgency is the marketing. Nothing in this category has ever required a same-day decision from a patient.
How to verify any of this yourself
FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. State boards publish their own actions. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
What regulatory change does and does not touch
It rarely changes the prescription requirement, the pharmacy licensing framework or the clinical review. It routinely changes price, which programmes operate, and what may be compounded at scale. Several large platforms left the compounded market during 2026 for exactly these reasons.
The practical defences are boring: do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 20 programmes we price, that runs from $145 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
4 of those programmes charge a recurring platform fee on top of medication and 19 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
4 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded semaglutide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
How to check this against the primary record
Regulatory summaries age badly, this one included. FDA publishes its compounding pages, its shortage database and its warning letters, all free and searchable by company name. Where this page and the agency disagree, the agency is right.
Three things get conflated in coverage of this area: a proposal, an enforcement action and a final rule. Only the third changes what is lawful.
What it changes for someone paying cash
Rarely the prescription requirement, the licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Five large programmes stopped selling compounded semaglutide during 2026 and patients generally found out at renewal.
The practical response is unglamorous: do not let supply run to zero, keep a prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Why regulatory news is used as a sales tool
Because urgency sells. A programme citing a rule change to push you into a twelve-month prepayment is using a genuine regulatory fact to manufacture a deadline that does not apply to you. Read the rule, not the email about the rule.
Reading this against the rest of the decision
This sits inside a decision with three parts: what you pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.
They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interruption is a clinical event rather than an inconvenience — semaglutide takes sixteen weeks to re-titrate from the starter dose.
Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest on the site.
What to do with this before you enrol
Turn it into two or three questions you can send in an email. Anything here that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.
The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.
If a programme declines to answer, that is an answer. The market currently offers 20 priced alternatives, the cheapest verified at $145 a month all-in at a maintenance dose.
What this page assumes about you
That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.
Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 20 cash prices spanning $145 to $324.
The bias we can see in our own data
We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.
It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 12 tracked programmes appear here with an explanation instead of a number because of it.
What we deliberately do not measure
Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.
That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.
The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.
The switching cost nobody prices
Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.
The second is expensive. Sixteen weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.
How much ftc weight-loss advertising rules should weigh
Less than the dose question and more than the brand. 19 of 20 programmes hold one price from 0.25 mg to 2.4 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.
That is because semaglutide titrates slowly. Sixteen weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.
Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.
What a well-run programme publishes
Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished semaglutide base from salt forms and linked the salts to safety concerns.
That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.